^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Opdivo (nivolumab)

    i
    Other names: NSC-748726, GTPL 7335, BMS936558, BMS 936558, GTPL-7335, MDX1106, MDX 1106, ONO4538, ONO 4538, NSC748726, ONO-4538, BMS-936558, MDX-1106, NSC 748726, ono-0123, GTPL7335
    Company:
    BMS, Ono Pharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    23h
    CVM-008: CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=95, Recruiting, TaiRx, Inc. | Trial primary completion date: Sep 2025 --> Mar 2026
    Trial primary completion date
    |
    Opdivo (nivolumab)
    1d
    LONESTAR: Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=339, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    1d
    Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (clinicaltrials.gov)
    P2, N=340, Active, not recruiting, Replimune Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation
    |
    Opdivo (nivolumab) • Tudriqev (vusolimogene oderparepvec-wtpg)
    1d
    Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma (clinicaltrials.gov)
    P1/2, N=13, Terminated, John Kirkwood | Trial completion date: Dec 2028 --> Feb 2025 | Active, not recruiting --> Terminated; Secura Bio, Inc. discontinued support of the trial.
    Trial completion date • Trial termination
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • Inlyta (axitinib) • Copiktra (duvelisib)
    1d
    A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer (clinicaltrials.gov)
    P1, N=27, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | N=40 --> 27 | Trial completion date: Aug 2026 --> Dec 2025 | Trial primary completion date: Aug 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel
    1d
    TRIDeNT: Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    BRAF mutation • BRAF V600
    |
    Opdivo (nivolumab) • Mekinist (trametinib) • Tafinlar (dabrafenib) • Mektovi (binimetinib) • Braftovi (encorafenib)
    2d
    Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) (clinicaltrials.gov)
    P2, N=494, Not yet recruiting, Melanoma Institute Australia | Trial completion date: Sep 2037 --> Jan 2038 | Trial primary completion date: Dec 2027 --> Mar 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    2d
    CIME: Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (clinicaltrials.gov)
    P3, N=132, Recruiting, Centre Leon Berard | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition • dMMR
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    3d
    FORTITUDE-102: Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (clinicaltrials.gov)
    P3, N=515, Active, not recruiting, Amgen | Trial primary completion date: Jan 2026 --> Oct 2025
    Trial primary completion date
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • bemarituzumab (AMG 552)
    3d
    IMCODE-004: A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC) (clinicaltrials.gov)
    P2, N=362, Recruiting, Hoffmann-La Roche | Trial primary completion date: Nov 2028 --> Mar 2029
    Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • autogene cevumeran (RG6180)
    3d
    A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer (clinicaltrials.gov)
    P2, N=144, Recruiting, Ono Pharmaceutical Co. Ltd | Not yet recruiting --> Recruiting | Initiation date: Jul 2025 --> Nov 2025
    Enrollment open • Trial initiation date • MSI-H • dMMR
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • BMS-986310
    3d
    Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation (clinicaltrials.gov)
    P2, N=20, Recruiting, City of Hope Medical Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    clonoSEQ
    |
    Opdivo (nivolumab) • Imbruvica (ibrutinib) • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV